首页> 美国卫生研究院文献>PLoS Clinical Trials >The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations
【2h】

The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations

机译:p16Ink4A表达模式在神经内分泌和非神经内分泌肺肿瘤中的对比作用:临床病理和分子相关性的综合分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lung cancer encompasses a constellation of malignancies with no validated prognostic markers. p16Ink4A expression has been reported in different subtypes of lung cancers; however, its prognostic value is controversial. Here, we sought to investigate the clinical significance of p16Ink4A immunoexpression according to specific staining patterns and its operational implications. A total of 502 tumors, including 277 adenocarcinomas, 84 squamous cell carcinomas, 22 large cell carcinomas, 47 typical carcinoids, 12 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 32 small cell carcinomas were reviewed and subjected to immunohistochemical analysis for p16Ink4A and Ki67. The spectrum of p16Ink4A expression was annotated for each case as negative, sporadic, focal, or diffuse. Expression at immunohistochemical level showed intra-tumor homogeneity, regardless tumor histotype. Enrichments in cells expressing p16Ink4A were observed from lower- to higher-grade neuroendocrine malignancies, whereas a decrease was seen in poorly and undifferentiated non-neuroendocrine carcinomas. Tumor proliferation indices were higher in neuroendocrine tumors expressing p16Ink4A while non-neuroendocrine malignancies immunoreactive for p16Ink4A showed a decrease in Ki67-positive cells. Quantitative statistical analyses including each histotype and the p16Ink4A status confirmed the independent prognostic role of p16Ink4A expression, being a high-risk indicator in neuroendocrine tumors and a marker of good prognosis in non-neuroendocrine lung malignancies. In this study, we provide circumstantial evidence to suggest that the routinary assessment of p16Ink4A expression using a three-tiered scoring algorithm, even in a small biopsy, may constitute a reliable, reproducible, and cost-effective substrate for a more accurate risk stratification of each individual patient.
机译:肺癌包括一系列恶性肿瘤,没有经过验证的预后指标。 p16 Ink4A 的表达已报道在不同亚型的肺癌中。但是,其预后价值尚有争议。在这里,我们试图根据特定的染色模式及其操作意义,研究p16 Ink4A 免疫表达的临床意义。审查了总共502种肿瘤,包括277例腺癌,84例鳞状细胞癌,22例大细胞癌,47例典型类癌,12例非典型类癌,28例大细胞神经内分泌癌和32例小细胞癌,并进行了免疫组织化学分析,结果p16 Ink4A 和Ki67。 p16 Ink4A 表达谱在每种情况下均标注为负,零星,聚焦或弥散。不论肿瘤的组织类型如何,在免疫组织化学水平上的表达均显示出肿瘤内的同质性。从低至高级别的神经内分泌恶性肿瘤中观察到表达p16 Ink4A 的细胞的富集,而在分化较差和未分化的非神经内分泌癌中则见下降。表达p16 Ink4A 的神经内分泌肿瘤的肿瘤增殖指数较高,而对p16 Ink4A 免疫反应的非神经内分泌恶性肿瘤的Ki67阳性细胞减少。定量统计分析包括每种组织类型和p16 Ink4A 状态,证实了p16 Ink4A 表达的独立预后作用,它是神经内分泌肿瘤的高风险指标和良好预后的标志物在非神经内分泌性肺恶性肿瘤中。在这项研究中,我们提供的间接证据表明,即使在小规模的活检中,使用三层评分算法对p16 Ink4A 表达的常规评估也可能构成可靠,可重复且经济高效的方法为每个患者提供更准确的风险分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号